Bioengineering with Endothelial Progenitor Cells Improves the Vascular Engraftment of Transplanted Human Islets

Liza Grapensparr¹, Gustaf Christoffersson¹, and Per-Ola Carlsson¹,²

Abstract
Pancreatic islets isolated for transplantation are disconnected from their vascular supply and need to establish a new functional network posttransplantation. Due to poor revascularization, prevailing hypoxia with correlating increased apoptosis rates in experimental studies can be observed for months posttransplantation. Endothelial progenitor cells (EPCs) are bone marrow–derived cells that promote neovascularization. The present study tested the hypothesis that EPCs, isolated from human umbilical cord blood, could be coated to human islet surfaces and be used to promote islet vascular engraftment. Control or EPC bioengineered human islets were transplanted into the renal subcapsular space of nonobese diabetic/severe combined immunodeficiency mice. Four weeks posttransplantation, graft blood perfusion and oxygen tension were measured using laser Doppler flowmetry and Clark microelectrodes, respectively. Vessel functionality was also assessed by in vivo confocal imaging. The vascular density and the respective contribution of human and recipient endothelium were assessed immunohistochemically by staining for human and mouse CD31. Islet grafts with EPCs had substantially higher blood perfusion and oxygen tension than control transplants. Furthermore, analysis of the vascular network of the grafts revealed that grafts containing EPC bioengineered islets had a superior vascular density compared with control grafts, with functional chimeric blood vessels. We conclude that a simple procedure of surface coating with EPCs provides a possibility to improve the vascular engraftment of transplanted human islets. Established protocols are also easily applicable for intraportal islet transplantation in order to obtain a novel directed cellular therapy at the site of implantation in the liver.

Keywords
endothelial progenitor cells, islet revascularization, neovascularization, islet engraftment

Introduction
The metabolically active pancreatic islets are highly vascularized, with a blood perfusion regulated to match the different metabolic demands for oxygen and nutrient supply of the endocrine cells¹. The islet vasculature also supports β cell growth, differentiation, and function by paracrine interactions²–⁶ and provides drainage of secreted hormones to the central circulation.

Pancreatic islets isolated for transplantation are disconnected from their vascular supply and need to establish a new functional network posttransplantation. Due to poor revascularization, prevailing hypoxia with correlating increased apoptosis rates in experimental studies can be observed for months posttransplantation, not only at the renal subcapsular site⁷,⁸ but also at the clinically used intraportal site⁹,¹⁰. It is therefore desirable to find a therapeutic alternative that allows for better revascularization shortly posttransplantation.

Endothelial progenitor cells (EPCs) were first described in 1997 by Asahara et al.¹¹. These proangiogenic cells are recruited from the bone marrow in response to a vascular injury and contribute to neovascularization by incorporation into the damaged vasculature¹²–¹⁴, as well as through the release of different angiogenic and proinflammatory factors¹⁵–¹⁸. Peripheral mobilization of EPCs and other bone marrow–derived cells by granulocyte-macrophage colony-stimulating factor were previously shown to enhance
pancreatic islet revascularization and function after intraportal transplantation. However, this technique has not been implemented clinically, possibly in fear of evoking an immune rejection of the graft. More recently, EPCs have instead been mixed together with rodent or porcine islets and shown to increase islet vascular density and β cell function posttransplantation in rodents.

The present study tested the possibility to improve engraftment of transplanted human islets by EPCs. In order to establish a clinically useful protocol, which is also applicable to the intraportal site, a simple coating procedure was developed, where EPCs attached to the islet surface. Moreover, in order to exclude that the previously observed increased revascularization by EPCs merely reflected dysfunctional blood vessels, in vivo imaging, blood perfusion, and oxygen tension measurement techniques were applied for the first time to quantify their functional relevance.

### Materials and Methods

#### Animals

Male nonobese diabetic/severe combined immunodeficiency mice (Taconic M&B, Ejby, Denmark) weighing 25 to 30 g were used in all experiments. The animals were housed under standardized conditions (12 h light/12 h dark cycle) and had free access to water and pelleted food.

#### Islet Isolation and Culture

Human islets were obtained from the Nordic Network for Islet Isolation. Islets were isolated from 11 brain-dead donors (8 males, 3 females; see Table 1 for donor characteristics) and transplanted within 6 to 14 d after isolation. The human islets were cultured at 37 °C and 5% CO₂ in Connaught Medical Research Laboratories (CMRL) 1066 media (Gibco, Grand Island, NY, USA) containing 10% (vol/vol) fetal calf serum (Sigma-Aldrich, St. Louis, MO, USA), 50 mmol/L l-glutamine (Sigma-Aldrich), and 5 U/mL penicillin-streptomycin (Roche Applied Science, Penzberg, Germany) prior to transplantation.

#### EPC Culture and Coating Procedure

EPCs from human umbilical cord blood (AMS Biotechnology, Abingdon, United Kingdom) were used at passages 6 and 7. The obtained cells had been characterized by their expression of CD146, CD34, vascular endothelial growth factor receptor 2, von Willebrand factor, low-density lipoprotein uptake, and lectin binding. The cells were defined as late EPCs, since they did not express CD133. Their functional capacity was confirmed by tube formation and migration assays by AMS Biotechnology. Cells in our lab were cultured in T75 flasks (Corning Life Sciences, Corning, NY, USA), with endothelial progenitor outgrowth cell (EPOC) media (AMS Biotechnology). In order to coat EPCs to the islet surface prior to transplantation, the islets were incubated at 37 °C with 10,000 EPCs per islet for 1 h under gentle shaking. This number of EPCs per islet was chosen based on pilot experiments, where full coverage of the human islet surfaces was observed within 1 h of coinoculation.

#### Cell Tracking

In order to determine the fate of the EPCs, 1 batch of cells were labeled using Qtracker 625 cell-labeling kit (Life Technologies, Carlsbad, CA, USA) prior to transplantation.

#### Islet Transplantation

Animals were anesthetized by an intraperitoneal injection of Avertin (0.015 mL/g body weight of a 2.5% (vol/vol) solution of 10 g 97% (vol/vol) 2,2,2-tribromoethanol [Sigma-Aldrich] in 10 mL 2-methyl-2-butanol [Kemila, Stockholm, Sweden]). A small incision was made at the left subcostal flank, exposing the kidney. Two hundred control or EPC bioengineered human islets were transplanted into the renal subcapsular space. In separate experiments, control and EPC bioengineered human islets were instead transplanted into the abdominal external oblique muscle (for technique, see the study by Christoffersson et al.23).

#### Blood Flow and Oxygen Tension

One-month posttransplantation, the mice were again anesthetized by Avertin and maintained at body temperature on a surgical table. A polyethylene catheter was inserted into the right carotid artery and thereafter connected to a blood pressure transducer (ADInstruments, Dunedin, New Zealand). Another incision was made at the left subcostal flank. The kidney was freed from its surrounding tissues and immobilized in a plastic cup, with a clear view of the graft. Graft and kidney blood perfusion were measured using laser Doppler flowmetry with a needle probe (Transonic BLF 21 Series, probe diameter 1.2 mm; Transonic, Ithaca, NY, USA).

### Table 1. Characteristics of Donors Used in This Study.

<table>
<thead>
<tr>
<th>Donor</th>
<th>Gender</th>
<th>Age</th>
<th>BMI</th>
<th>Dynamic Index</th>
<th>Isolation Transplantation (d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>M</td>
<td>74</td>
<td>25.6</td>
<td>4.5</td>
<td>6</td>
</tr>
<tr>
<td>II</td>
<td>M</td>
<td>53</td>
<td>26.1</td>
<td>11.1</td>
<td>8</td>
</tr>
<tr>
<td>III</td>
<td>M</td>
<td>52</td>
<td>28</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>IV</td>
<td>M</td>
<td>59</td>
<td>21.4</td>
<td>6.1</td>
<td>8</td>
</tr>
<tr>
<td>V</td>
<td>F</td>
<td>58</td>
<td>38.1</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>VI</td>
<td>M</td>
<td>58</td>
<td>23.4</td>
<td>8.7</td>
<td>13</td>
</tr>
<tr>
<td>VII</td>
<td>M</td>
<td>62</td>
<td>26.3</td>
<td>6.9</td>
<td>10</td>
</tr>
<tr>
<td>VIII</td>
<td>F</td>
<td>60</td>
<td>21.2</td>
<td>34.1</td>
<td>6</td>
</tr>
<tr>
<td>IX</td>
<td>M</td>
<td>65</td>
<td>23.1</td>
<td>4.5</td>
<td>14</td>
</tr>
<tr>
<td>X</td>
<td>M</td>
<td>38</td>
<td>29.3</td>
<td>2.7</td>
<td>13</td>
</tr>
<tr>
<td>XI</td>
<td>F</td>
<td>56</td>
<td>22</td>
<td>3.6</td>
<td>8</td>
</tr>
</tbody>
</table>

Abbreviations: BMI = body mass index; M = male; F = female.
Cryosections were made with a thickness of 8 μm. Immunohistochemistry immobilized for imaging using a vacuum window. A Zeiss LSM 5 LIVE microscope (Carl Zeiss AG, Oberkochen, Germany), with a Plan-Apochromat 20×/0.8 objective, was used for all in vivo imaging.

**In Vivo Imaging**

Mice transplanted with control or EPC bioengineered human islets to striated muscle in the abdominal wall were at 2 wk posttransplantation anesthetized by isoflurane and maintained at body temperature on a surgical table. An intravenous injection of Alexa Fluor 488-conjugated rat anti-mouse CD31 (BioRad, Hercules, CA, USA) and APC-conjugated mouse anti-human CD31 (eBioscience, San Diego, CA, USA) was performed. The antibodies were allowed to circulate at body temperature for a minimum of 5 min prior to imaging. An incision was made to the skin to expose the graft, and the muscle was snap-frozen in liquid nitrogen. The kidney was thereafter removed and snap-frozen in liquid nitrogen.

**Confocal Imaging and Islet Vascular Density Assessment**

Confocal imaging was performed using a laser scanning confocal microscope Zeiss LSM 780 (Carl Zeiss AG) with a Plan-Apochromat 20×/0.8 M27 objective. Zeiss Zen Blue edition software, version 1.1.1.0 (Carl Zeiss AG) was used for all image analyses. Islet vascular density was assessed by measuring human and mouse CD31-positive areas within IA2-positive areas (Islet Antigen-2 [IA2] is a ubiquitous marker for islet endocrine cells).

**Statistical Analysis**

All data are presented means ± Standard error of the mean (SEM). Paired and unpaired Student’s t-test was used for comparison between control and bioengineered grafts. For all comparisons, a P value of <0.05 was considered significant. All statistical analyses were carried out using GraphPad Prism Version 6.0 (GraphPad Software, San Diego, CA, USA).

**Results**

**EPC Bioengineered Human Islets**

By incubating islets together with EPCs for 1 h under gentle shaking, the surface of the islets became covered with EPCs. After prolonged culture (48 h) of some of the islets, the EPCs were still attached to the surface, indicating a strong cell-to-surface binding (Fig. 1A and B).

**Human Islets Contained Endothelial Cells at the Time of Transplantation**

The images of human islets in vitro showed that many of these islets still contained remnant endothelial cells after 8 to 16 d of culture (Fig. 1A and B). There was no difference in remnant donor endothelial cells between the groups at the time of transplantation.

**Human Islets Coated with EPCs Had a Higher Vascular Density**

EPC bioengineered grafts at the renal subcapsular site had an increased islet vascular density when compared with control transplants at 1 mo posttransplantation (Fig. 2A to E; n = 8 in both groups). This reflected a doubled area of blood vessels of both mouse (recipient) and human origin.
EPCs Were Incorporated into Functional Blood Vessels

By labeling EPCs prior to transplantation, these cells could be traced and imaged within the renal subcapsular grafts. The observed overlap between labeled EPCs and lectin confirmed that EPCs were incorporated into functional blood vessels at 1 mo posttransplantation (Fig. 2F; \(n = 3\)).

Grafts Containing EPCs Had Significantly Higher Blood Perfusion and Oxygen Tension

In order to assess the functionality of the newly formed graft vessels, blood perfusion and oxygen tension were measured within the human islet grafts and surrounding kidney tissue. The blood perfusion in EPC bioengineered grafts (\(n = 8\)) was more than double that of control grafts (\(n = 9\)) 1 mo posttransplantation (Fig. 3A). Moreover, the EPC containing grafts had a 3-fold increase in oxygen tension when compared with control grafts (Fig. 3B). Meanwhile, the blood perfusion and oxygen tension of the kidney cortex did not differ between the groups (Fig. 3C and D).

Functional Chimeric Vessels Were Present in EPC Bioengineered Grafts

To further assess the functionality of the newly formed vessels, islets were transplanted to the striated muscle of the abdominal wall in 7 animals. This transplantation site enabled for easy visualization of the islet grafts within the living animals. This imaging confirmed that the donor (human) and recipient (mouse) vessels connect within the grafts to form functional (blood perfused) vessels (Fig. 4A and B). The EPC bioengineered grafts also contained functional chimeric (Fig. 4B and C) blood vessels (i.e., vessels of both human and mouse origin), further supporting the finding that EPCs incorporate into ingrowing blood vessels.

Discussion

Poor engraftment of the implanted tissue constitutes a major challenge for successful clinical islet transplantation. In the present study, we describe a simple procedure of surface-coating islets with EPCs prior to transplantation and show this to be a highly effective mean to improve the revascularization of human islet grafts. The formed blood vessels were found highly functional and more than doubled the blood perfusion and oxygen tension in the tissue at 1 mo posttransplantation.

Previous studies of transplanted murine islets have shown that islet endothelial cells disappear within the first days during islet culture. In contrast, the results of the present study indicated that human islet endothelial cells remain even after prolonged culture of the human islets, thereby providing a possibility for these endothelial cells to participate in the newly formed vascular network of the islets posttransplantation. The reason for this striking difference is presently obscure. However, besides the species difference, studies of murine islet endothelial cells in culture indicate that they are highly susceptible to glucose toxicity and that their apoptosis rates could substantially be decreased by lowering the glucose concentration during culture. Similarly, glucose has been shown to inhibit angiogenesis of isolated human islets. It is noteworthy that the clinical protocols, as well as the present study, used a lower glucose concentration (5.6 mmol/L) for islet culture than that commonly applied for rodent islet cultures (11 mmol/L).

The EPCs used in the present study did not express CD133 and are thus considered to be late EPCs, also known...
as EPOCs\textsuperscript{31}, in contrast to the originally described early EPCs obtained from circulating adult peripheral blood nuclear cells\textsuperscript{11}. It has been proposed that early and late EPCs contribute to the neovascularization in different ways; early EPCs are suggested to release angiogenic cytokines that are thought to attract more endothelial cells to the site of injury, while late EPCs mainly provide the area with sufficient numbers of endothelial cells for the neovasculogenesis to occur and do so by differentiating into mature endothelial cells\textsuperscript{12}. Nevertheless, also, late EPCs produce a multitude of angiogenetic factors, including matrix metalloproteinase 2 and vascular endothelial growth factor (VEGF)\textsuperscript{17}, and cord blood–derived late EPCs have recently been observed to promote angiogenesis by mere paracrine factors\textsuperscript{32}. Indeed, the higher number of blood vessels in EPC bioengineered islet grafts in the present study was observed to result not only from an incorporation of the EPCs into the capillary networks but also from an increased ingrowth of recipient vessels (mouse) and proliferation of residual human endothelial cells. Previous studies indicate that EPCs may

![Fig. 2. Vascular density of control and endothelial progenitor cell (EPC) bioengineered grafts. Vascularization of control (A and B) and EPC-coated human islets (C and D) at 1 mo posttransplantation. Contribution of ingrowing recipient (mouse) endothelial cells was evaluated by mouse CD31 staining (red), whereas human endothelial cell contribution was assessed by human CD31 staining (green). The endocrine mass was visualized by the ubiquitous islet endocrine marker IA2 (yellow) in (A) and (C). (E) Quantification of vascular density and the respective contribution of mouse and human endothelial cells in the grafts of control (closed bars) and EPC-coated human islets (open bars) are shown (n = 8 in both groups). (F) At 1 mo posttransplantation, many of the transplanted EPCs (yellow = Qtracker 625) were incorporated (indicated by white arrows) into functional vessels (green = bound soybean agglutinin lectin). Scale bars correspond to 200 \( \mu \text{m} \) (A), 100 \( \mu \text{m} \) (C), and 50 \( \mu \text{m} \) (F). All values are given as means ± standard error of the mean for 8 transplanted animals in each group. *\( P < 0.05 \) when compared to control islet grafts.](image-url)
trigger angiogenesis in rodent and porcine islets by either stimulating the VEGF-A expression in the transplanted β cells or the secretion of VEGF-A directly from the EPCs. Another mechanism may be that microvesicles from EPCs transfer RNA stimulating angiogenesis in tissue. Whereas Oh et al., similar to us, reported that both donor and recipient endothelium, as well as the transplanted EPCs, contributed to the newly formed blood vessels, the inclusion of EPCs in blood vessels was not observed by Kang and colleagues. Discrepancies between studies are likely explained by different characteristics of the transplanted EPCs, but perhaps also species differences. Importantly, in
the present study of human islets, we show that the grafts with EPCs acquire a much higher vascular density than control grafts, and that inclusion of EPCs does not only enhance the speed of revascularization as reported previously\textsuperscript{22}.

One month posttransplantation, the area of blood vessels in islet grafts containing EPCs was almost doubled when compared with control islet grafts. Although this has also been reported for murine islets with murine EPCs\textsuperscript{20}, those and our findings could have been explained by expansion of transplanted EPCs or remnant endothelial cells in the tissue, without the formation of functional perfused blood vessels. We therefore investigated the formed blood vessels for functionality by different techniques. Firstly, that the vascular structures, including those with incorporated EPCs and remnant endothelium, were perfused and were confirmed by both intravenous lectin infusion and in vivo imaging. Secondly, the recordings of blood perfusion by laser Doppler flowmetry showed that the blood perfusion levels in the grafts of EPC-coated islets were much higher than in control grafts and similar to those in the highly blood-perfused renal cortex. In this context, it may be noted that at least in rodents, the blood perfusion of native islets is similar to that in the renal cortex\textsuperscript{1,34}. Thirdly, the oxygen tension levels in the grafts of EPC-coated islets was restored to that of native rodent islets\textsuperscript{35}, suggesting optimal oxygen delivery to the transplanted \(\beta\) cells.

In the chosen study design, the islets were transplanted beneath the kidney capsule and to striated muscle to enable functional evaluation of the formed vasculature by in vivo microscopy and direct blood perfusion and oxygen tension measurements. However, although not tested in the present study, the established protocols are also easily applicable for intraportal islet transplantation in order to obtain a novel directed cellular therapy at the site of implantation in the liver. Normoglycemic and not hyperglycemic recipient mice were used in the study, which may have influenced the results. However, in the clinical situation, efforts are applied to obtain strict metabolic control posttransplantation, and, at least for the revascularization of murine islets, the process is independent of the glycemic state of the recipient\textsuperscript{36}. Native EPCs of patients with diabetes are essentially defective in both numbers and function\textsuperscript{37,38}, which provide an important rationale for their substitution in islet transplantation, although they, at least in animal models, in lower numbers may home to transplanted islets\textsuperscript{39}. EPCs for bioengineering pancreatic islets can easily be obtained from peripheral blood of adult patients or, as in the present study, from umbilical cord blood. Heightened HLA sensitization may occur if including EPCs with islets, but this may be solved by using islet donor- or recipient-derived EPCs.

**Acknowledgments**

The skilled technical assistance of Dr. Zhanchun Li and Mrs. Lisbeth Sagulin, Department of Medical Cell Biology, Uppsala University, is gratefully acknowledged. We are also grateful to Professor Asahara and Tokai University for providing the opportunity for Liza Grapensparr to visit and learn EPC culture and expansion techniques as well as to the Nordic Network for Clinical Islet Transplantation for their generous support with human islet preparations.

**Ethical Approval**

All animal experiments were approved by Uppsala’s Ethical Committee on Animal Experiments (C124/15). All experiments involving human islets were approved by the Regional Ethical Review Board in Uppsala (Ups 02/290).

**Statement of Human and Animal Rights**

All experiments were conducted in accordance with Swedish human and animal protection laws.

**Statement of Informed Consent**

This study made use of human islets from the pancreas of deceased brain-dead donors. The organs were provided to the Nordic Network for Clinical Islet Transplantation for clinical or research use according to the Swedish laws for organ donation.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Swedish Research Council, EXODIAB, StemTherapy, Torsten Söderberg Foundation, the EFSD/JDRF/Novo Nordisk Programme 2012, the Swedish Diabetes Association, the Swedish Child Diabetes Foundation, Diabetes Wellness Sverige, the Novo Nordisk Foundation, Olle Engkvist Byggmästare Fund, and AFA.

**References**

5. Olerud J, Mokhtari D, Johansson M, Christoffersson G, Lawler J, Welsh N, Carlsson PO. Thrombospondin-1: an islet...


